J
Juan Maurel
Researcher at University of Barcelona
Publications - 69
Citations - 2121
Juan Maurel is an academic researcher from University of Barcelona. The author has contributed to research in topics: Colorectal cancer & KRAS. The author has an hindex of 20, co-authored 69 publications receiving 1813 citations.
Papers
More filters
Journal ArticleDOI
Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial
E. Van Cutsem,M. Nowacki,István Láng,Stefano Cascinu,I. Shchepotin,Juan Maurel,Ph. Rougier,David Cunningham,Johannes Nippgen,C.-H. Köhne +9 more
TL;DR: The present trial investigated the effectiveness of cetuximab in combination with standard F OLFIRI compared with FOLFIRI alone in the first-line treatment of pts with epidermal growth factor receptor (EGFR)-expressing mCRC.
Journal ArticleDOI
A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer
Marc Ychou,Werner Hohenberger,S. Thezenas,Matilde Navarro,Juan Maurel,Carsten Bokemeyer,E. Shacham-Shmueli,Fernando Rivera,C. Kwok-Keung Choi,Armando Santoro +9 more
TL;DR: FOLFIRI in the adjuvant treatment of LMCRC showed no significant improvement in DFS compared with LV5FUs, and was compared with simplified 5-FU/FA in this setting.
Journal ArticleDOI
Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial
Carlos Fernández-Martos,Xabier García-Albéniz,Carles Pericay,Juan Maurel,Jorge Aparicio,C. Montagut,M.J. Safont,Antonieta Salud,R. Vera,B. Massuti,Pilar Escudero,Vicente Alonso,Carlos Bosch,Marta Martin,Bruce D. Minsky +14 more
TL;DR: Given the lower acute toxicity and improved compliance with induction CT compared with adjuvant CT, integrating effective systemic therapy before CRT and surgery is a promising strategy and should be examined in phase III trials.
Journal ArticleDOI
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy
E. Van Cutsem,Salvatore Siena,Yves Humblet,J-L Canon,Juan Maurel,Emilio Bajetta,Bart Neyns,D Kotasek,Armando Santoro,Werner Scheithauer,S Spadafora,R Amado,N Hogan,Marc Peeters +13 more
TL;DR: These findings are comparable to those from the phase 3 study and support panitumumab monotherapy for chemorefractory colorectal cancer.
Journal ArticleDOI
Clinical relevance of colorectal cancer molecular subtypes
Nuria Rodríguez-Salas,Gema Domínguez,Rodrigo Barderas,Marta Mendiola,Xabier García-Albéniz,Juan Maurel,Jaime Feliu Batlle +6 more
TL;DR: The different molecular classifications of CRC could have potential applications to prognosis, but also to therapeutical approaches of the CRC patients are reviewed to clarify their clinical and therapeutical relevance.